Ticker

Agreement with Spartan Medical opens adds a channel to the U.S. government healthcare market, supplementing existing U.S. commercial distribution and 18 foreign countries. WESTMINSTER, CA / ACCESS Newswire / September 3, 2026 / BioLargo, Inc. (OTCQX:BLGO), a cleantech and life sciences company, today announced that its subsidiary Clyra Medical Technologies is expanding distribution of its FDA-cleared ViaCLYR™ wound…

WESTMINSTER, CA / ACCESS Newswire / September 1, 2026 / BioLargo, Inc. (OTCQX:BLGO), a cleantech and life sciences innovator and engineering services solution provider, today announced that Dennis P. Calvert, President and Chief Executive Officer, will participate in the inaugural Nasdaq / LD Micro Summit on Wednesday, September 9, 2026.

Profitability This table compares BioLargo and Akzo Nobel's net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets BioLargo -11.45% -39.90% -22.06% Akzo Nobel 9.76% 9.43% 3.69% Earnings and Valuation This table compares BioLargo and Akzo Nobel"s gross revenue, earnings per share and valuation. Gross Revenue Price/Sales Ratio

Former U.S. EPA senior executive Sally Gutierrez will represent BioLargo at the investor event. WESTMINSTER, CA / ACCESS Newswire / August 25, 2026 / BioLargo, Inc. (OTCQX:BLGO), a cleantech and life sciences company, today announced that it will participate in Gabelli Funds' 4th Annual PFAS Symposium on September 24, 2026, in New York City.

PALM BEACH, Fla., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Gabelli is hosting its 4th Annual PFAS Symposium on September 24th, 2026, in New York City.